Article
Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Molecular cancer therapeutics - 1 May 2019
Shatsky Rebecca, Parker Barbara A, Bui Nam Q, Helsten Teresa, Schwab Richard B, Boles Sarah G, Kurzrock Razelle
Abstract excerpt
Clinical-grade next-generation sequencing (NGS) of tissue- and blood-derived circulating tumor DNA (ctDNA) allows assessment of multiple genomic alterations in patients with cancer. We analyzed ctDNA (54-70 genes) in 62 patients with advanced breast cancer (median = five prior therapies); 38 also had tissue NGS (236-315 genes). Overall, 42 of 62 patients (68%) had detectable (characterized) ctDNA alterations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
